The rise of Sildenafil initially fueled a boom for pharma, but recent developments present a uncertain outlook for those considering a stake. Generic alternatives are eroding revenue, and ongoing patent challenges add https://mohamadjjwk930569.goabroadblog.com/39951312/sildenafil-and-big-pharma-a-risky-play